Micronised tissue allografts - MiMedx

Drug Profile

Micronised tissue allografts - MiMedx

Alternative Names: Dehydrated human amnion/chorion membrane - MiMedx; dHACM allografts

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MiMedx
  • Class Anti-inflammatories; Cell therapies; Tissue extracts
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Plantar fasciitis
  • Phase II Wounds
  • Clinical Phase Unknown Shoulder injuries
  • Preclinical Ischaemia

Most Recent Events

  • 04 Aug 2017 MiMedx filed with the US FDA to initiate an Investigational New Drug phase III Achilles Tendonitis clinical trial
  • 04 Aug 2017 MiMedx intends to file with the US FDA an Investigational New Drug for a clinical trial of micronised dHACM in Osteoarthritis Knee Pain by the end of third quarter of 2017
  • 04 Aug 2017 MiMedx intends to submit a Biologic License Application to the US FDA for Tendinitis upon the completion of Plantar Fasciitis phase III trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top